CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	37.31	371.21	1.2	914.96	0.72
Revenue Growth (YoY)	-89.95%	30885.48%	-99.87%	127154.94%	-99.75%
Cost of Revenue	430.9	517.58	571.9	441.75	269.41
Gross Profit	-393.59	-146.38	-570.7	473.22	-268.69
Selling, General & Admin	72.98	76.16	102.46	99.69	85.75
Operating Expenses	72.98	76.16	102.46	99.69	85.75
Operating Income	-466.57	-222.54	-673.16	373.53	-354.44
Interest & Investment Income	103.9	71.82	22.66	6	-
Other Non Operating Income (Expenses)	-	-	-	-	6.38
EBT Excluding Unusual Items	-362.67	-150.72	-650.5	379.53	-348.06
Pretax Income	-362.67	-150.72	-650.5	379.53	-348.06
Income Tax Expense	3.59	2.89	-0.33	1.87	0.81
Earnings From Continuing Operations	-366.25	-153.61	-650.18	377.66	-348.87
Net Income	-366.25	-153.61	-650.18	377.66	-348.87
Net Income to Common	-366.25	-153.61	-650.18	377.66	-348.87
Shares Outstanding (Basic)	84	79	78	76	66
Shares Outstanding (Diluted)	84	79	78	80	66
Shares Change (YoY)	6.49%	1.90%	-3.29%	21.90%	15.84%
EPS (Basic)	-4.34	-1.94	-8.36	4.97	-5.29
EPS (Diluted)	-4.34	-1.94	-8.36	4.70	-5.29
Free Cash Flow	-144.68	-269.85	-532.93	457.27	-256.72
Free Cash Flow Per Share	-1.72	-3.41	-6.86	5.69	-3.89
Gross Margin	-	-39.43%	-	51.72%	-
Operating Margin	-1250.38%	-59.95%	-56190.40%	40.82%	-49295.55%
Profit Margin	-981.54%	-41.38%	-54271.70%	41.28%	-48520.86%
Free Cash Flow Margin	-387.72%	-72.69%	-44484.89%	49.98%	-35705.70%
EBITDA	-447.31	-202.7	-648.99	391.48	-345.25
EBITDA Margin	-	-54.61%	-	42.79%	-
D&A For EBITDA	19.26	19.84	24.17	17.95	9.18
EBIT	-466.57	-222.54	-673.16	373.53	-354.44
EBIT Margin	-	-59.95%	-	40.82%	-
Effective Tax Rate	-	-	-	0.49%	-
Revenue as Reported	37.31	371.21	1.2	914.96	0.72

Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q